Personalized anti-rejection therapy with alemtuzumab for kidney transplant recipients

References

• 1. Clayton PA, McDonald SP, Russ GR, Chadban SJ. Long-term outcomes after acute rejection in kidney transplant recipients: An ANZDATA analysis. J. Am. Soc. Nephrol. 30(9), 1697–1707 (2019).
  Medline CASGoogle Scholar
• 2. Rampersad C, Balshaw R, Gibson IW et al. The negative impact of T cell-mediated rejection on renal allograft survival in the modern era. Am. J. Transplant. 22(3), 761–771 (2022).
  Medline CASGoogle Scholar
• 3. Ho J, Okoli GN, Rabbani R et al. Effectiveness of T cell-mediated rejection therapy: a systematic review and meta-analysis. Am. J. Transplant. 22(3), 772–785 (2022).
  MedlineGoogle Scholar
• 4. Mayrdorfer M, Liefeldt L, Wu K et al. Exploring the complexity of death-censored kidney allograft failure. J. Am. Soc. Nephrol. 32(6), 1513–1526 (2021).
  Medline CASGoogle Scholar
• 5. Loupy A, Haas M, Roufosse C et al. The Banff 2019 Meeting report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am. J. Transplant. 20(9), 2318–2331 (2020).
  Medline CASGoogle Scholar
• 6. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. 9(Suppl. 3), S1–S155 (2009).
  MedlineGoogle Scholar
• 7. van den Hoogen MW, Hoitsma AJ, Hilbrands LB. Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation. Expert. Opin. Biol. Ther. 12(8), 1031–1042 (2012).
  MedlineGoogle Scholar
• 8. van der Zwan M, Clahsen-Van Groningen MC, Roodnat JI et al. The efficacy of rabbit anti-thymocyte globulin for acute kidney transplant rejection in patients using calcineurin inhibitor and mycophenolate mofetil-based immunosuppressive therapy. Ann. Transplant. 23, 577–590 (2018).
  MedlineGoogle Scholar
• 9. van der Zwan M, Baan CC, van Gelder T, Hesselink DA. Review of the clinical pharmacokinetics and pharmacodynamics of alemtuzumab and its use in kidney transplantation. Clin. Pharmacokinet. 57(2), 191–207 (2018).
  MedlineGoogle Scholar
• 10. Hanaway MJ, Woodle ES, Mulgaonkar S et al. ; INTAC Study Group. Alemtuzumab induction in renal transplantation. N. Engl. J. Med. 364(20), 1909–1919 (2011).
  Medline CASGoogle Scholar
• 11. 3C Study Collaborative Group, Haynes R, Harden P, Judge P et al. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C study): a randomised trial. Lancet 384(9955), 1684–1690 (2014).
  MedlineGoogle Scholar
• 12. van den Hoogen MW, Hesselink DA, van Son WJ, Weimar W, Hilbrands LB. Treatment of steroid-resistant acute renal allograft rejection with alemtuzumab. Am. J. Transplant. 13(1), 192–196 (2013).
  MedlineGoogle Scholar
• 13. van der Zwan M, Clahsen-Van Groningen MC, van den Hoogen MWF et al. Comparison of alemtuzumab and anti-thymocyte globulin treatment for acute kidney allograft rejection. Front. Immunol. 11, 1332 (2020).
  MedlineGoogle Scholar
• 14. Betjes MGH, Kho MML, Litjens NHR, de Weerd AE, Roodnat JI. Alemtuzumab as second-line treatment for late antibody-mediated rejection of transplanted kidneys. Transplant. Proc. 53(7), 2206–2211 (2021).
  Medline CASGoogle Scholar
• 15. Bouvy AP, Klepper M, Betjes MG, Weimar W, Hesselink DA, Baan CC. Alemtuzumab as antirejection therapy: T cell repopulation and cytokine responsiveness. Transplant. Direct 2(6), e83 (2016).
  MedlineGoogle Scholar
• 16. van der Zwan M, Leebeek FWG, Sandberg Y, Kruip MJHA, Hesselink DA. Acquired haemophilia A after alemtuzumab therapy. Haemophilia 26(6), e337–e339 (2020).
  MedlineGoogle Scholar
• 17. van der Zwan M, Hesselink DA, Brusse E et al. Guillain–Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients. Neurol. Neuroimmunol. Neuroinflamm. 7(4), e721 (2020).
  MedlineGoogle Scholar
• 18. Willicombe M, Goodall D, McLean AG, Taube D. Alemtuzumab dose adjusted for body weight is associated with earlier lymphocyte repletion and less infective episodes in the first year post renal transplantation. A retrospective study. Transplant. Int. 30(11), 1110–1118 (2017).
  Medline CASGoogle Scholar
• 19. Guthoff M, Berger K, Althasu K et al. Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients. BMC Nephrology 21(1), 178 (2020).
  Medline CASGoogle Scholar
• 20. Hullegie-Peelen DM, van der Zwan M, Clahsen-van Groningen MC et al. Clinical and molecular profiling to develop a potential prediction model for the response to alemtuzumab therapy for acute kidney transplant rejection. Clin. Pharmacol. Ther. 111(5), 1155–1164 (2022).
  Medline CASGoogle Scholar
• 21. Mengel M, Loupy A, Haas M et al. Banff 2019 Meeting report: molecular diagnostics in solid organ transplantation. Consensus for the Banff human organ transplant (B- HOT) gene panel and open source multicenter validation. Am. J. Transplant. 20(9), 2305–2317 (2020).
  MedlineGoogle Scholar
• 22. Admiraal R, Jol-van der Zijde CM, Furtado Silva JM et al. Population pharmacokinetics of alemtuzumab (Campath) in pediatric hematopoietic cell transplantation: towards individualized dosing to improve outcome. Clin. Pharmacokinet. 58(12), 1609–1620 (2019).
  Medline CASGoogle Scholar
• 23. Meesters-Ensing JJ, Admiraal R, Ebskamp L et al. Therapeutic drug monitoring of anti-thymocyte globulin in allogeneic stem cell transplantation: proof of concept. Front. Pharmacol. 13, 828094 (2022).
  Medline CASGoogle Scholar
• 24. Lin TS, Flinn IW, Modali R et al. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 105(1), 289–291 (2005).
  Medline CASGoogle Scholar
• 25. Keller CW, Ruck T, McHugh D et al. Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis. Ann. Clin. Transl. Neurol. 6(12), 2586–2594 (2019).
  Medline CASGoogle Scholar
• 26. Ternant D, Büchler M, Thibault G et al. Influence of FcγIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients. Pharmacogenet. Genom. 24(1), 26–34 (2014).
  Medline CASGoogle Scholar
• 27. Ternant D, Arnoult C, Pugnière M et al. IgG1 allotypes influence the pharmacokinetics of therapeutic monoclonal antibodies through FcRn binding. J. Immunol. 196(2), 607–613 (2016).
  Medline CASGoogle Scholar
• 28. Loupy A, Aubert O, Orandi BJ et al. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ 366, 41923 (2019).
  Google Scholar
• 29. Udomkarnjananun S, Townamchai N, Kerr SJ et al. The first Asian kidney transplantation prediction models for long-term patient and allograft survival. Transplantation 104(5), 1048–1057 (2020).
  MedlineGoogle Scholar
• 30. Kaboré R, Haller MC, Harambat J, Heinze G, Leffondré K. risk prediction models for graft failure in kidney transplantation: a systematic review. Nephrol. Dial. Transplant. 32(Suppl. 2), ii68–ii76 (2017).
  MedlineGoogle Scholar
• 31. Gonzales MM, Bentall A, Kremers WK, Stegall MD, Borrows R. Predicting individual renal allograft outcomes using risk models with 1-year surveillance biopsy and alloantibody data. J. Am. Soc. Nephrol. 27(10), 3165–3174 (2016).
  MedlineGoogle Scholar
• 32. Viglietti D, Loupy A, Aubert O et al. Dynamic prognostic score to predict kidney allograft survival in patients with antibody-mediated rejection. J. Am. Soc. Nephrol. 29(2), 607–619 (2018).
  Google Scholar
• 33. Rekers NV, de Fijter JW, Claas FHJ, Eikmans M. Mechanisms and risk assessment of steroid resistance in acute kidney transplant rejection. Transplant. Immunol. 38, 3–14 (2016).
  Medline CASGoogle Scholar
• 34. Rekers NV, Flaig TM, Mallat MJK et al. Donor genotype and intragraft expression of CYP3A5 reflect the response to steroid treatment during acute renal allograft rejection. Transplantation 101(9), 2017–2025 (2017).
  Medline CASGoogle Scholar